» Articles » PMID: 25494018

Differential Expression of Vascular Endothelial Growth Factor-a Isoforms in Neovascular Age-related Macular Degeneration

Overview
Journal Retina
Date 2014 Dec 11
PMID 25494018
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To investigate the role of vascular endothelial growth factor-A (VEGF-A) isoforms in neovascular age-related macular degeneration.

Methods: Choroidal neovascular membranes (CNV) were excised in 24 patients, 8 of them underwent previous photodynamic therapy. All procedures were performed before anti-VEGF therapies were implemented in Germany. Normal human donor eyes served as controls. Messenger RNA expression of total VEGF-A and VEGF-A isoforms was measured.

Results: Vascular endothelial growth factor-A121 is the most abundant isoform in CNV and control tissues. In controls, VEGF-A121 is lowest in neural retina and highest in choroids. For total VEGF-A and VEGF-A165, this is vice versa. VEGF-A165 and VEGF-A189 are significantly higher in CNV than in control choroids, the opposite is found for VEGF-A121. After photodynamic therapy, total VEGF-A and VEGF-A121 are increased, VEGF-A165 and VEGF-A189 are decreased. Age-dependently, there is an increase in VEGF-A165 and a decrease in VEGF-A121.

Conclusion: Vascular endothelial growth factor-A isoforms are differentially distributed, suggesting that tissue-specific regulation of various isoforms is physiologically important. The disruption of this homeostasis in CNV membranes may be significant in the onset and progression of neovascular age-related macular degeneration. Our findings support the dominant role of VEGF-A121 in neovascular age-related macular degeneration but hint that VEGF-A165 may have an equivalent role in other neovascular retinal pathology.

Citing Articles

Efficacy, Safety and Immunogenicity of Sun's Ranibizumab Biosimilar in Neovascular Age-Related Macular Degeneration: A Phase 3, Double-Blind Comparative Study.

Ghosh A, Nikumbh U, Shukla C, Laul R, Dixit A, Mahapatra S Ophthalmol Ther. 2024; 13(5):1369-1382.

PMID: 38530568 PMC: 11039601. DOI: 10.1007/s40123-024-00883-5.


Curcumin and Wnt/β‑catenin signaling in exudative age‑related macular degeneration (Review).

Vallee A Int J Mol Med. 2022; 49(6).

PMID: 35445729 PMC: 9083851. DOI: 10.3892/ijmm.2022.5135.


Treatment Landscape of Macular Disorders in Indian Patients with the Advent of Razumab™ (World's First Biosimilar Ranibizumab): A Comprehensive Review.

Sharma S, Sharma T, Prasad S, Gopalakrishnan M, Chaturvedi A Ophthalmol Ther. 2021; 10(3):431-443.

PMID: 34155608 PMC: 8216589. DOI: 10.1007/s40123-021-00362-1.


Safety and efficacy of Razumab™ (world's first biosimilar ranibizumab) in wet age-related macular degeneration: a post-marketing, prospective ASSET study.

Sharma S, Gupta V, Maiti A, Natesh S, Saxena S, Dave V Int J Retina Vitreous. 2021; 7(1):24.

PMID: 33762008 PMC: 7992797. DOI: 10.1186/s40942-021-00293-w.


Inhibition of laser induced rats choroidal neovascularization by intravitreous injection of sEphB4-HSA.

He S, Ouyang S, Li X, Ma B Ann Transl Med. 2021; 9(1):18.

PMID: 33553311 PMC: 7859820. DOI: 10.21037/atm-20-3810.